The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)
Abstract
Angiotensin receptor blockade and neprilysin (NEP) inhibition together offer potential benefits for the treatment of hypertension and heart failure. LCZ696 is a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). Oral administration of LCZ696 caused dose‐dependent increases in atrial natriuretic peptide immunoreactivity (due to NEP inhibition) in Sprague‐Dawley rats and provided sustained, dose‐dependent blood pressure reductions in hypertensive double‐transgenic rats. In healthy participants, a randomized, double‐blind, placebo‐controlled study (n = 80) of single‐dose (200–1200 mg) and multiple‐dose (50–900 mg once daily for 14 days) oral administration of LCZ696 showed that peak plasma concentrations were reached rapidly for valsartan (1.6–4.9 hours), AHU377 (0.5–1.1 hours), and its active moiety, LBQ657 (1.8–3.5 hours). LCZ696 treatment was associated with increases in plasma cGMP, renin concentration and activity, and angiotensin II, providing evidence for NEP inhibition and angiotensin receptor blockade. In a randomized, open‐label crossover study in healthy participants (n = 56), oral LCZ696 400 mg and valsartan 320 mg were shown to provide similar exposure to valsartan (geometric mean ratio [90% confidence interval]: AUC 0‐∞ 0.90 [0.82–0.99]). LCZ696 was safe and well tolerated. These data support further clinical development of LCZ696, a novel, orally bioavailable, dual‐acting angiotensin receptor—NEP inhibitor (ARNi) for hypertension and heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potter, L. R., Abbey-Hosch, S., & Dickey, D. M. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0014 · Cited by 1,002
Kostis, J. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.09.014 · Cited by 579
Angiotensin I converting enzyme.
Erdös, E. G. (1975) · Circulation Research · doi:10.1161/01.res.36.2.247 · Cited by 544
Azizi, M., & Ménard, J. (2004) · Circulation · doi:10.1161/01.cir.0000131449.94713.ad · Cited by 199
Rubattu, S., Sciarretta, S., Valenti, V., Stanzione, R., & Volpe, M. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2008.174 · Cited by 195
Natriuretic peptides and therapeutic applications
Lee, C. Y. W., & Burnett, J. C. (2007) · Heart Failure Reviews · doi:10.1007/s10741-007-9016-3 · Cited by 182
Richards, M., Wittert, G., Crozier, I., Espiner, E. A., Yandle, T. G., Ikram, H., & Frampton, C. M. (1993) · Journal of Hypertension · doi:10.1097/00004872-199304000-00011 · Cited by 145
Fryer, R. M., Segreti, J., Banfor, P. N., Widomski, D. L., Backes, B. J., Lin, C. W., Ballaron, S. J., Cox, B. F., Trevillyan, J. M., Reinhart, G. A., et al. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707641 · Cited by 130
High Human Renin Hypertension in Transgenic Rats
Bohlender, J. M., Fukamizu, A., Lippoldt, A., Nomura, T., Dietz, R., Ménard, J., Murakami, K., Luft, F. C., & Ganten, D. (1997) · Hypertension · doi:10.1161/01.hyp.29.1.428 · Cited by 130
Baxter, G. F. (2004) · Basic Research in Cardiology · doi:10.1007/s00395-004-0457-8 · Cited by 102
Cited by
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Pathological Ventricular Remodeling: Mechanisms: Part 1 of 2
Burchfield, J. S., Xie, M., & Hill, J. A. (2013) · Circulation · doi:10.1161/circulationaha.113.001878 · Cited by 766
Ruilope, L. M., Dukat, A., Böhm, M., Lacourcière, Y., Gong, J., & Lefkowitz, M. P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61966-8 · Cited by 599
Heart Failure With Preserved Ejection Fraction: Mechanisms, Clinical Features, and Therapies
Sharma, K., & Kass, D. A. (2014) · Circulation Research · doi:10.1161/circresaha.115.302922 · Cited by 508
Metadata
- Authors
- Gu, J., Noe, A., Chandra, P., Al‐Fayoumi, S., Ligueros‐Saylan, M., Sarangapani, R., Maahs, S., Ksander, G., Rigel, D. F., Jeng, A. Y., Lin, T., Zheng, W., & Dole, W. P.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2010-04
- Volume
- 50
- Issue
- 4
- Pages
- 401-414
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2032130572
- Cited by
- 505
- References
- 14
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi). https://app.cochat.ai/papers/10.1177/0091270009343932
- The paper
- Gu, J., Noe, A., Chandra, P., Al‐Fayoumi, S., Ligueros‐Saylan, M., Sarangapani, R., Maahs, S., Ksander, G., Rigel, D. F., Jeng, A. Y., Lin, T., Zheng, W., & Dole, W. P. (2010). Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi). The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270009343932
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.